The Claim
Fat mass loss induced by bimagrumab in adults with obesity and type 2 diabetes is maintained for at least 12 weeks after the last dose.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity and type 2 diabetes, fat mass lost during treatment with bimagrumab remains reduced for at least 12 weeks after stopping the drug.
See the scientific wording
Fat mass loss induced by bimagrumab in adults with obesity and type 2 diabetes is maintained for at least 12 weeks after the last dose, suggesting a durable effect beyond the treatment period.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing fat and break down existing fat. The new muscle mass stays increased and the fat loss persists even after the drug is stopped.
What the research says
1 studyThe study showed that when people with obesity and type 2 diabetes took bimagrumab, they lost a lot of fat, and even after they stopped taking the drug, the fat didn’t come back for at least 12 weeks. This means the effect lasted beyond the treatment time.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.